Cite
Bazo-Alvarez JC, Pal K, Pham TM, et al. Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice. Sci Rep. 2021;11(1):23826doi: 10.1038/s41598-021-02670-9.
Bazo-Alvarez, J. C., Pal, K., Pham, T. M., Nazareth, I., Petersen, I., & Sharma, M. (2021). Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice. Scientific reports, 11(1), 23826. https://doi.org/10.1038/s41598-021-02670-9
Bazo-Alvarez, Juan Carlos, et al. "Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice." Scientific reports vol. 11,1 (2021): 23826. doi: https://doi.org/10.1038/s41598-021-02670-9
Bazo-Alvarez JC, Pal K, Pham TM, Nazareth I, Petersen I, Sharma M. Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice. Sci Rep. 2021 Dec 13;11(1):23826. doi: 10.1038/s41598-021-02670-9. PMID: 34903733.
Copy
Download .nbib